Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)
2600 Kelly Road
Warrington
Pennsylvania
18976
United States
Tel: 215-488-9300
Fax: 215-488-9301
Website: http://www.discoverylabs.com/
337 articles with Windtree Therapeutics, Inc. (Formerly Known As Discovery Laboratories, Inc.)
-
Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
5/13/2021
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the first quarter ended March 31, 2021 and provided key business updates.
-
Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent
4/19/2021
Windtree Therapeutics, Inc. today announced it has filed a Track One prioritized application with the United States Patent and Trademark Office (USPTO) for a patent stemming from an application it filed previously under the Patent Cooperation Treaty (PCT).
-
Windtree Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides Key Business Updates
3/29/2021
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the fourth quarter and year ended December 30, 2020 and provided key business updates.
-
Windtree Therapeutics Announces Closing of $30.0 Million Public Offering
3/25/2021
Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the closing of its previously announced public offering of 9,230,500 shares of its common stock
-
Windtree Therapeutics Announces Pricing of $30.0 Million Public Offering
3/23/2021
Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the pricing of its previously announced public offering of 9,230,500 shares of our common stock
-
Windtree Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
3/22/2021
Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has commenced an underwritten public offering of its shares of common stock and warrants to purchase shares of common stock
-
Windtree Extends Scientific Collaboration in Heart Failure Studying Its SERCA2a Activators with the University of Milan-Bicocca
3/22/2021
Collaboration to focus on the continued development of chronic heart failure treatment SERCA2a activator compounds adding to Windtree's acute treatment Istaroxime
-
Windtree to Present at the Oppenheimer 31st Annual Healthcare Conference
3/15/2021
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser , president and chief executive officer, will present at the Oppenheimer 31 st Annual Healthcare Conference
-
Windtree to Present at the H.C. Wainwright Global Life Sciences Conference
3/8/2021
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser , president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference
-
Windtree Announces Issuance of New U.S. Patent Covering Technology on Its Redesigned AEROSURF® Device
2/16/2021
Windtree Therapeutics, Inc., a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,874,818, covering features of the aerosol delivery system for the Company's AEROSURF® drug delivery device.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Windtree Strengthens Its Board by Appointing Three New Directors
2/4/2021
Company welcomes Dr. Evan Loh, Ms. Leslie Williams and Dr. Rob Scott, seasoned executives with deep cardiovascular development and commercial experience.
-
Windtree Appoints Dr. Joseph Soffer to Lead Cardiovascular Clinical Development
2/1/2021
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the appointment of Joseph Soffer, M.D., F.A.C.C., as Executive Director of Clinical Development, effective immediately
-
BioSpace spoke to executives from four companies about their expectations for the conference and the coming year.
-
Windtree Announces First Patient Dosed in its Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19
1/6/2021
The Phase 2 study will evaluate key physiological measures and is expected to be completed in 3-6 months
-
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
-
Windtree Announces First Patient Dosed in Phase 2 Study of Istaroxime for the Acute Treatment of Early Cardiogenic Shock in Heart Failure Patients
10/1/2020
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has dosed the first pa
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 30, 2020.
-
Windtree Announces FDA Acceptance of IND Application for a Phase 2 Clinical Trial Studying KL4 Surfactant in Acute Lung Injury in Adults with COVID-19
9/29/2020
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for a Phase 2 clinical trial studying lyo lucinactant
-
Windtree to Present at H.C. Wainwright 22nd Annual Global Investment Conference
9/8/2020
Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Frasier, president and chief executive officer, will present at the H.C. Wainwright 22 nd Annual Global Inve